The FDA standardized bioequivalence administration protocols across product-specific guidances for generic chewable oral solid dosage forms. The regulatory update aims to align administration approaches with harmonized international testing standards. For generic manufacturers, the move can reduce variability in protocol design and streamline preparation for BE submissions, potentially affecting timelines for lifecycle management and product launches. —